BioPharmX (NASDAQ:BPMX) shares saw an uptick in trading volume on Wednesday after an insider bought additional shares in the company. 1,356,384 shares traded hands during trading, an increase of 445% from the previous session’s volume of 249,006 shares.The stock last traded at $0.31 and had previously closed at $0.28.

Specifically, Director Stephen Morlock purchased 428,571 shares of the business’s stock in a transaction dated Monday, November 28th. The shares were purchased at an average cost of $0.35 per share, with a total value of $149,999.85. Following the completion of the purchase, the director now owns 543,956 shares of the company’s stock, valued at approximately $190,384.60. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Separately, HC Wainwright reissued a “buy” rating on shares of BioPharmX in a research note on Saturday, September 17th.

The stock’s market cap is $9.66 million. The company’s 50 day moving average price is $0.29 and its 200 day moving average price is $0.57.

TRADEMARK VIOLATION NOTICE: “BioPharmX (BPMX) Sees Strong Trading Volume Following Insider Buying Activity” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/30/biopharmx-bpmx-sees-strong-trading-volume-following-insider-buying-activity.html.

About BioPharmX

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NASDAQ:BPMX

Receive News & Stock Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related stocks with our FREE daily email newsletter.